Rotavirus vaccine bovine reassortant - Serum Institute of India

Drug Profile

Rotavirus vaccine bovine reassortant - Serum Institute of India

Alternative Names: Bovine reassortant rotavirus vaccine - Serum Institute of India; BRV-PV; LBRV-PV; Live attenuated bovine-human reassortant rotavirus vaccine

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Serum Institute of India
  • Developer PATH; Serum Institute of India
  • Class Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rotavirus infections

Most Recent Events

  • 28 Oct 2015 PATH, in collaboration with Serum Institute of India, plans a phase III trial for Rotavirus infections (In infants, Prevention) in India (NCT02584816)
  • 01 May 2014 Phase-III clinical trials in Rotavirus infections (prevention in infants) in India (PO)
  • 23 May 2013 Serum Institute of India plans a phase III trial for Rotavirus infections (prevention in infants) in India (CTRI/2013/05/003667)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top